An important paper related to our work measuring liver fat on calcium scans showing semaglutide lowers liver fat in our prospective randomized trial - "STOP Trial" .@novonordisk @bdi_ai.

An excellent expert consensus document on statins in geriatrics. Also advocates for CAC scanning to help decision making (IIa recommendation). i am a strong advocate of treating older active adults with statins.

Further, it is absolutely incorrect to directly compare to our natural history abstract (unpublished), without matching, correcting for baseline plaque and methodologic differences. We will ultimately compare the cohorts. Very disappointed in your reporting of our discussion.

Gil - you paraphrased me incorrectly, it is unfortunate and i regret taking time to discuss with you. Simply the April 7th version of the paper was approved by all, fully peer reviewed and in press. The final paper will have the non-calcified plaque volumes. All need to wait.

An excellent paper from my fellow Angelo De La Rosa who published great work on predicting CHF with CAC scans from MESA - continuing work we have been doing for > 20 years.

RT @nicknorwitz: This Position Statement from Principle Investigator @BudoffMd ended up as dispersed tweets. I've compiled them for clarity….

This is the first of a set of papers, with more published data coming soon. I would ask fellow professionals to keep social media dialogue civil and suggest especially that those parties without experience conducting research keep their juvenile attacks to themselves.

Dr Alo, as you have published ZERO papers in your lifetime, and have no credibility in the field, calling my work dishonest is not acceptable. The change in NCPV was less than the change in PAV%, as shown in figure 1 in the paper, so if anything we put our worst foot forward.

Finally, these patients were on no other treatments, anti-hypertensives, statins, or other therapies to slow plaque, so a true natural history study, different from many other drug therapy studies. @AdrianSotoMota @nicknorwitz @bschermd@realDaveFeldman @khurramn1 @JACCJournals.

This is the first of a set of papers, with more published data coming soon. I would ask fellow professionals to keep social media dialogue civil and especially that those parties without experience conducting research keep their juvenile attacks to themselves.

Importantly —in the population at large (including those with and without CAC at baseline), neither LDL nor ApoB predicted plaque progression, whereas baseline plaque predicted plaque progression. This is novel, a contribution to the literature, and warrants further investigation.

However, this does not mean that this population is immune to atherosclerosis — obviously. Like any population, the KETO-CTA participants exhibited a heterogeneous risk profile, and a minority exhibited more rapid progression, as expected.

These lean, metabolically healthy individuals on a #ketodiet exhibited less coronary plaque and lower rates of plaque progression than I would have expected, with the majority exhibiting minimal progression and several exhibiting regression. This is interesting.

There has been a tremendous amount of interest in our new paper:.1/5) While we appreciate the interest, there have been some comments that are unbecoming of fellow clinicians and academics. Let me clarify key points in this thread 🧵👇. **.

a nice short paper on when is too young for a CAC scan?.

Completed another prospective serial CCTA trial, this one with Repatha from the great Cedars Sinai team under Dan Berman MD-

These are certainly interesting and important data. We look forward to studying further the unique risk profile of Lean Mass Hyper-Responders. They have a lot to teach us.

#Inflammation plays a substantial role in the formation & progression of atherosclerotic plaque leading to #heartdisease. The EKSTROM trial data shows low-dose colchicine could significantly reduce total plaque volume after 1 year: .

Very proud of @JSharimMD for our new book on learning cardiac CT .